Stavudine (d4T, Zerit®)
Stavudine, 2′,3′-didehydro-3′-deoxythymidine (D4T), has recently been approved by the U.S. Food and Drug Administration for the treatment of advanced HIV-1 infection in adults who are 1) intolerant to approved therapies with proven clinical benefit, or 2) have experienced significant clinical or immunologic deterioration while receiving these therapies, or 3) for whom such therapies are contraindicated. Approval was based on studies in over 11,000 patients, almost all of whom had received prior zidovudine therapy, showing that stavudine had a beneficial effect upon surrogate markers and acceptable toxicity. The effect of stavudine in delaying progression of HIV disease awaits the completion of clinical trials which are currently in progress.
KeywordsHuman Immunodeficiency Virus Type Nucleoside Analog Nucleoside Analog Reverse Transcriptase Inhibitor Zidovudine Resistance Human Immunodeficiency Virus Isolate
Unable to display preview. Download preview PDF.
- 3.Riddler SA, Anderson RE, Mellors JW. Antiretroviral Activity of Stauvudine (2’, 3’-didehydro-3’deoxythynidine, D4T) J. Antiviral Research (in press).Google Scholar
- 4.Lin T-S, Schinazi RF, Prusoff WH. Potent and selective in vitro activity of 3’–deoxythymidin-2’–ene (3’–deoxy-2’, 3’ -didehydrothymidine) against human immunodeficiency birus. Biochem. Pharmacol. 1987; 36: 2713–2718.Google Scholar
- 9.Mellors JW, Dutschman GE, Im GJ, Tramontano E, Winkler SR, Cheng Y-C. In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase. Mo 1. Pharmacol. 1992; 41: 446–451.Google Scholar
- 10.Brankovan V, Tarantini K, Datema R, Chou TC. Strong synergistic anti-HIV activity of a purine and a pyrimidine nucleoside analog, ddI and d4T. V International Conference of AIDS, Montreal 1991; Abstract M.C.P. 128.Google Scholar
- 14.Kim GP, Brett-Smith H, Friedland GH, Chang CP, Griffith B, Prusoff W, Cheng YC, Toxicity and Pharmacokinetics of 2’3’ didehydro 3’deoxy thymidine (D4T) at low/moderate doses, 32 1CAAC, Anaheim Calif., 1992, Abstr. no. 561.Google Scholar
- 15.Brett-Smith H, Griffith B, Kim G, Walesky M, Friedland G. Magintude and duration of stavudine antiretroviral effect. First National Conference of Human Retroviruses and related Infections, Washington D.C., Dec. 1993.Google Scholar
- 16.Dunkle L, Anderson R, McLarin C et al, Stavudine: A Promising Anti-retroviral Agent VIII International Conference on AIDS, Amsterdam, 1992, Abstr. WEB 1011.Google Scholar
- 17.Dunkle LM, Pavia A, Messina M, Cross A, The BMS-019 Study Group, Stavudine (d4t) vs. zidovudine (ZDV) for the treatment of HIV-infected patients wit CD4 counts of 50-S00cells/mm3 following at least 6 months zidovudine, 34th ICAAC, Orlando Fla. 1994.Google Scholar
- 18.Smaldone L. Personal Communication.Google Scholar
- 20.Gonzalez C, Cheng YC, Griffith B, Friedland G, (unpublished).Google Scholar
- 21.Anderson RE, et al. Response to Stavudine (d4t) in Zidovudine naive subjects, 34th ICAAC, Orlando Fla. 1994.Google Scholar